Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT vs Standard Therapy in Decompensated Cirrhosis
NCT03014505Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fecal microbiome transplant in decompensated cirrhosis (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoint: Number of adverse events complication rate at 3 months. Status: unknown.
02
Drugs
fecal microbiome transplant
03
Conditions
decompensated cirrhosis
Beyond the preview
Go deeper on NCT03014505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014505.